Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
The National Institute of Child Health and Human Development Endocrinology & Genetics Section seeks parties interested in licensing tumor samples harboring novel stem cell factor FOXD3 variants.
